BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18231900)

  • 1. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Zent CS
    Leuk Lymphoma; 2008 Feb; 49(2):175-6. PubMed ID: 18231900
    [No Abstract]   [Full Text] [Related]  

  • 2. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
    Smith JA
    Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
    [No Abstract]   [Full Text] [Related]  

  • 3. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
    Lee D
    Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
    [No Abstract]   [Full Text] [Related]  

  • 4. Campath-1H for chronic lymphocytic leukemia.
    Rai KR
    Clin Lymphoma; 2002 Sep; 3(2):73-4. PubMed ID: 12435278
    [No Abstract]   [Full Text] [Related]  

  • 5. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
    Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
    Worth LJ; Thursky KA
    Leuk Lymphoma; 2006 Dec; 47(12):2435-6. PubMed ID: 17169785
    [No Abstract]   [Full Text] [Related]  

  • 7. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
    Thompson CA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
    [No Abstract]   [Full Text] [Related]  

  • 8. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
    Oberoi SS; Abou Jawde RM
    J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
    [No Abstract]   [Full Text] [Related]  

  • 9. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia.
    Cortelezzi A; Pasquini MC; Sarina B; Bertani G; Grifoni F; Colombi M; Lambertenghi Deliliers G
    Haematologica; 2005 Mar; 90(3):410-2. PubMed ID: 15749678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
    Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; SorĂ  F; Sica S; Efremov D; Leone G
    J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
    [No Abstract]   [Full Text] [Related]  

  • 11. Alemtuzumab.
    Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
    [No Abstract]   [Full Text] [Related]  

  • 12. Alemtuzumab in B-cell chronic lymphocytic leukemia.
    Shapira I; Grossbard ML
    Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
    Keating M; Hallek M
    Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
    [No Abstract]   [Full Text] [Related]  

  • 14. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
    Grey M
    Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab.
    Ammatuna E; Marino C; Mitra ME; Calvaruso G; Iannitto E
    Eur J Haematol; 2004 Sep; 73(3):225-6. PubMed ID: 15287923
    [No Abstract]   [Full Text] [Related]  

  • 17. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab.
    Pitini V; Arrigo C; Barresi G
    Br J Haematol; 2003 Nov; 123(4):565. PubMed ID: 14616955
    [No Abstract]   [Full Text] [Related]  

  • 18. Alemtuzumab for treatment of lymphoproliferative disorders.
    Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
    [No Abstract]   [Full Text] [Related]  

  • 19. A case report of successful alemtuzumab treatment of a B-CLL patient suffering from renal failure.
    Haslbauer F
    Ann Hematol; 2009 Apr; 88(4):399-400. PubMed ID: 19099306
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
    Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S
    Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.